Hillman

Hilleman Laboratories is a first-of-its-kind vaccine research and development organization established as a joint venture between Merck & Co. (MSD) and the Wellcome Trust. Headquartered in Singapore, the company focuses on developing affordable, high-impact vaccines and biologics specifically tailored for low- and middle-income countries (LMICs). Its business model combines the expertise of a major pharmaceutical company with the mission-driven focus of a global health foundation to address unmet medical needs in infectious diseases. Hilleman operates the ACES facility, a cGMP pilot manufacturing hub that supports end-to-end product development from concept to Phase 2 clinical trial materials.